Related Experiment Video
Updated: Jan 14, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Reply to: Oxaliplatin Dosing and Toxicity: A Cautionary Perspective on Efficacy
Eric Assenat1, Pierre Senesse1
1Eric Assenat, MD, PhD, Department of Medical Oncology, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France, Digestive Oncology Department, CHU Montpellier, Montpellier University, Montpellier, France; and Pierre Senesse, MD, PhD, Department of Clinical Nutrition and Gastroenterology, Montpellier Cancer Institute (ICM), Montpellier University, Montpellier, France.
No abstract available in PubMed .
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

